Apr 11, 2019
Gilbert Family Foundation Commits $11 Million to Combat Vision Loss in NF1 Patients
Apr 02, 2019
Dermelix Biotherapeutics Announces Partnership with EspeRare for Pivotal-stage Antenatal Protein Replacement Therapy for XLHED
Apr 02, 2019
GRAMMY-Nominated Thompson Square to Perform Benefit Concert to Raise Money for Rare Genetic Disorder
Mar 14, 2019
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
Mar 04, 2019
Moureen Wenik, Executive Director for Foundation for Ichthyosis & Related Skin Types (FIRST) Responds to American Airlines' Discrimination of Passengers
Feb 22, 2019
Phoenix Tissue Repair Doses First Patient in Phase 1/2 Clinical Trial of PTR-01 (BBP-589) for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Feb 12, 2019
InMed Pharmaceuticals Reports Second Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update
Feb 07, 2019
In Honor of Kids with Tumors, Wear Blue and Green on May Seventeen
Feb 05, 2019
InMed Pharmaceuticals to Report Second Quarter Fiscal 2019 Financial Results and Business Update on February 12, 2019
Jan 22, 2019
TWi Biotechnology Announces Last Patient Enrolled in Phase 2 Proof-of-Concept Study of AC-203 for Treatment of Epidermolysis Bullosa
Jan 03, 2019
InMed Pharmaceuticals to Present at Biotech Showcase 2019 on January 9, 2019
Dec 19, 2018
Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies
Dec 12, 2018
Gilbert Family Foundation Announces $12 Million Gene Therapy Initiative to Address Underlying Cause of NF1
Dec 11, 2018
Eiger BioPharmaceuticals Reports on 2018 R&D Day
Dec 11, 2018
Spanish Language Version of Pioneering Patient History Study Launched
Dec 06, 2018
Angelman Syndrome Foundation Expands Clinic Network Internationally
Dec 03, 2018
Eiger BioPharmaceuticals Announces FDA Acceptance of IND Application for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies
Nov 29, 2018
Tuberous Sclerosis Alliance Preclinical Consortium Announces New Staff and Company Members
Nov 29, 2018
VHLA Announces 2018 Research Grant Recipients
Nov 27, 2018
Constant Pharmaceuticals to Initiate Clinical Development of TXA127 for Epidermolysis Bullosa (EB)